Xencor, Inc. (XNCR) Valuation — DCF & Advanced Analysis | MarketCI

Navigation

Explore Analysis Investor Relations AI Assistant Compare Screener

Help Pricing Privacy Terms

Navigation

Explore Analysis Investor Relations AI Assistant Compare Screener

Help Pricing Privacy Terms

Xencor, Inc. (XNCR) Valuation — DCF & Advanced Analysis | MarketCI | MarketCI

XNCR

Market Closed

Xencor, Inc.

NASDAQHealthcare Biotechnology

260 employees

CEO: Bassil I. Dahiyat

Founded: 2013

$14.94

+$0.00(+NaN%)

Market Cap

1.11B

Beta

0.86

52W Range

N/A

Dividend Yield

0.00%

Overview Forecasts Fundamental Market Sentiment Valuation Ownership

Comprehensive Valuation

In-depth valuation analysis including DCF scenarios and peer comparisons.

AI Insight: Xencor trades 27.6% above a PERT-weighted fair value of $10.73, signaling potential overvaluation despite high confidence in valuation methods. A negative DCF contrasts with optimistic analyst targets and trading range, reflecting diverging market views. Financial health scores reveal strong liquidity and leverage but no profitability or efficiency, indicating execution risk amid growth challenges.

Enhanced Football Field Analysis

Loading comprehensive valuation data...

Fetching multi-methodology valuation ranges...

Explore XNCR

Overview

Key metrics and AI-powered insights

Forecast

Price targets and earnings estimates

Fundamentals

Income, balance sheet and cash flow

Valuation

P/E, DCF and valuation multiples